Reference health

The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages

https://doi.org/10.1158/2326-6066.cir-20-0555
CiteStamped reference-health badge
58/58 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

The 58 checked references that resolve
resolves10.1182/blood-2017-05-743203
How I treat myeloma with new agents
resolves10.1111/imr.12233
Targeting the bone marrow microenvironment in multiple myeloma
resolves10.1182/blood-2009-05-220285
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug–induced apoptosis
resolves10.1182/blood-2012-08-448548
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
resolves10.1111/j.1365-2141.2012.09154.x
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
resolves10.1016/j.ccell.2018.02.007
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
resolves10.1038/leu.2015.191
Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma
resolves10.1158/1078-0432.CCR-16-3122
The Promise of Targeting Macrophages in Cancer Therapy
resolves10.1182/blood-2016-01-695395
Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma
resolves10.1038/leu.2012.141
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
resolves10.1080/19420862.2015.1007813
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
resolves10.1158/1535-7163.MCT-17-0998
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
resolves10.1038/s41375-018-0114-0
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
resolves10.1016/S2352-3026(15)00197-0
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
resolves10.1084/jem.192.8.1183
Burkitt Lymphoma in the Mouse
resolves10.4049/jimmunol.177.10.7303
Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression
resolves10.1038/ni.1990
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses
resolves10.1038/nbt.1754
Integrative genomics viewer
resolves10.7150/jca.30102
High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens
resolves10.1038/bjc.2016.11
High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma
resolves10.1126/science.1244851
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
resolves10.1016/j.coi.2010.02.011
Awakening lineage potential by Ikaros-mediated transcriptional priming
resolves10.1073/pnas.0400983101
Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria
resolves10.12703/P6-13
The M1 and M2 paradigm of macrophage activation: time for reassessment
resolves10.1182/blood-2003-06-1984
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
resolves10.1038/nature22076
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
resolves10.4049/jimmunol.1502198
CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor– and Complement Receptor 3–Dependent Mechanisms
resolves10.1182/blood-2011-08-372425
Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells
resolves10.1016/j.coi.2012.01.010
The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
resolves10.4049/jimmunol.0713732
M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
resolves10.1016/j.immuni.2014.06.008
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
resolves10.1038/nature21076
Metabolic gatekeeper function of B-lymphoid transcription factors
resolves10.1038/leu.2016.214
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia
resolves10.1038/nature11247
An integrated encyclopedia of DNA elements in the human genome
resolves10.1111/j.1365-2141.2011.08689.x
Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response
resolves10.1038/ni.1920
The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection
resolves10.1182/blood-2015-02-628669
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
resolves10.1016/j.celrep.2015.08.033
TNF Counterbalances the Emergence of M2 Tumor Macrophages
resolves10.1016/j.celrep.2016.04.001
TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection
resolves10.1182/blood-2006-07-037754
Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells
resolves10.1038/leu.2015.331
Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia
resolves10.1038/nature14610
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
resolves10.1038/s41419-018-0290-x
Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization
resolves10.1182/blood-2018-05-852798
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
resolves10.1158/2326-6066.CIR-15-0025-T
Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma
resolves10.1158/1078-0432.CCR-15-0200
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
resolves10.1200/JCO.2014.59.9258
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
resolves10.1056/NEJMoa1607751
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
resolves10.1038/nri3088
Transcriptional regulation of macrophage polarization: enabling diversity with identity
resolves10.1016/S1471-4906(02)02302-5
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
resolves10.1101/gad.297002.117
The making of a lymphocyte: the choice among disparate cell fates and the IKAROS enigma
resolves10.1016/j.immuni.2009.01.014
Genome-wide Lineage-Specific Transcriptional Networks Underscore Ikaros-Dependent Lymphoid Priming in Hematopoietic Stem Cells
resolves10.4049/jimmunol.1800158
Dual Roles for Ikaros in Regulation of Macrophage Chromatin State and Inflammatory Gene Expression
resolves10.1111/imr.12209
Mi‐2/Nu<scp>RD</scp> chromatin remodeling complexes regulate B and T‐lymphocyte development and function
resolves10.1007/s00296-010-1576-1
Down-regulated expression of IKZF1 mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
resolves10.1038/ng.472
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
resolves10.1080/2162402X.2015.1016699
Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation
resolves10.1038/s41409-019-0449-9
G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1158/2326-6066.cir-20-0555"><img src="https://citestamp.com/citestamped/10.1158/2326-6066.cir-20-0555/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1158/2326-6066.cir-20-0555/badge.svg)](https://citestamp.com/citestamped/10.1158/2326-6066.cir-20-0555)